Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
Titel:
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
Auteur:
Rinaldi, Yves Pointet, Anne-Laure Khemissa Akouz, Faiza Le Malicot, Karine Wahiba, Bidaut Louafi, Samy Gratet, Alain Miglianico, Laurent Laharie, Hortense Bouhier Leporrier, Karine Thirot Bidault, Anne Texereau, Patrick Coriat, Romain Terrebonne, Eric Gouttebel, Marie-Claude Malka, David Bachet, Jean-Baptiste Lepage, Côme Taieb, Julien